Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected Posted on September 9, 2024September 25, 2024 by recce_com Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected
Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024 Posted on September 6, 2024September 25, 2024 by recce_com Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024
Recce Pharmaceuticals – Executive Interview Posted on August 7, 2024September 25, 2024 by recce_com Recce Pharmaceuticals – Executive Interview
Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million Posted on August 5, 2024September 25, 2024 by recce_com Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million
Recce scores US$2M deal from US Department of Defense for burn wound infections gel Posted on July 16, 2024September 25, 2024 by recce_com Recce scores US$2M deal from US Department of Defense for burn wound infections gel
Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel Posted on July 15, 2024September 25, 2024 by recce_com Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel
Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327 Posted on June 28, 2024September 25, 2024 by recce_com Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
Recce Starts Phase 2 R327 Gel trial for bacterial skin infections Posted on June 25, 2024September 25, 2024 by recce_com Recce Starts Phase 2 R327 Gel trial for bacterial skin infections
Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327 Posted on June 18, 2024September 25, 2024 by recce_com Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327
Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound Posted on June 12, 2024September 25, 2024 by recce_com Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound
